RxDoctor Payments Data

Veronica Johnson, MD

Internal Medicine · Chicago, ILNPI 1033536412

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 81.2% of it on its own, with 8 other manufacturers making up the rest. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$101,119in general payments, 2019–2025

Across 178 payments — averaging $568.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$82K
  • Novo Nordisk$12K
  • Eli Lilly$6K
  • W. L. Gore & Associates, Inc.$214
  • Boston Scientific$187
  • Radius Health, Inc.$116
  • plus $141 from 3 others

What the payments were for

  • Consulting fees$15,81016%
  • Speaking & faculty fees$60,30060%
  • Travel & lodging$21,00121%
  • Food & beverage$3,7944%
  • Education$2140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,119 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$20,017
Medicare patients
88
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide133$150,171
OzempicSemaglutide123$145,658
TrulicityDulaglutide34$40,098
WegovySemaglutide25$37,877
Metformin Hcl ErMetformin Hcl121$856
Topiramate41$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$82,153$190,269167 claims
Novo NordiskOzempic, Wegovy$11,891$183,534148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →